MAPT and Alzheimer disease: Half of the participants had a family member with AD, and 26.9% had undergone AD screening, specifically short questionnaires (24.6%), followed by blood sample (9.7%), MRI or PET scan (9.7%), pathological biomarkers (Aβ and tau proteins) (2.3%), or a combination of different diagnostics (53.7%).